Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Low-dose Versus High-dose Sirolimus Combined With Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: a Randomized Noninferiority Trial
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The goal of this randomized clinical trial is to evaluate if low-dose sirolimus combined with prednisolone is noninferior to high-dose sirolimus combined with prednisolone in managing kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon (KHE with KMP) in pediatric patients. In this study, the low-dose regimen targets a sirolimus trough concentration of 4-8 ng/mL, while the standard high-dose regimen targets a trough concentration of 10-15 ng/mL. The main questions it aims to answer are:
Does the combination of low-dose sirolimus (target trough 4-8 ng/mL) and prednisolone achieve a noninferior objective response rate (including platelet count recovery and tumor volume reduction) compared to the high-dose sirolimus (target trough 10-15 ng/mL) and prednisolone combination at the primary endpoint evaluation? Does the low-dose sirolimus combination significantly reduce treatment-related toxicities and adverse events compared to the high-dose sirolimus combination?
Researchers will compare a low-dose sirolimus plus prednisolone arm to a standard high-dose sirolimus plus prednisolone arm to see if lowering the sirolimus dose within this combination regimen can maintain comparable therapeutic control over KMP while minimizing dose-dependent adverse effects.
Participants will:
Be randomized in a 1:1 ratio to receive either oral low-dose sirolimus combined with prednisolone (targeting a trough level of 4-8 ng/mL) or standard high-dose sirolimus combined with prednisolone (targeting a trough level of 10-15 ng/mL).
Undergo regular clinical evaluations, including physical examinations and serial blood tests to monitor peripheral platelet counts and sirolimus trough levels.
Receive routine imaging studies (such as MRI or ultrasound) to assess changes in tumor volume.
Be closely monitored throughout the study period for combination therapy-related side effects and systemic corticosteroid-associated adverse events.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Yi Ji, PhD
- Numéro de téléphone: 02885423453
- E-mail: jijiyuanyuan@163.com
Sauvegarde des contacts de l'étude
- Nom: Jiangyuan Zhou, MD
- E-mail: 13668491160@163.com
Lieux d'étude
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- West China Hospital of Sichuan University
-
Sous-enquêteur:
- Jiangyuan Zhou, MD
-
Contact:
- Yi Ji, PhD
- Numéro de téléphone: +862885423453
- E-mail: jijiyuanyuan@163.com
-
Contact:
- Jiangyuan Zhou, MD
- E-mail: 13668491160@163.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
Presenting a KHE with the following characteristics:
- Clinical features and histological findings consistent with progressive, non-resectable KHE associated with KMP.
- Patients must be 0 - 18 years of age at the time of study entry.
- Without functional impairment requiring treatment of corticosteroid.
Organ function requirements:
1 Adequate liver function:
- Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and
- ALT and AST less than or equal to 2.5 x upper limit normal (ULN) for age.
2 Adequate renal function:
- 0-5 years of age maximum serum creatinine (mg/dL) of 0.8
- 6-10 years of age maximum serum creatinine (mg/dL) of 1.0
- 11-15 years of age maximum serum creatinine (mg/dL) of 1.2
- 16-18 years of age maximum serum creatinine (mg/dL) of 1.5
- Adequate bone marrow function: Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter.
- Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.
Exclusion Criteria:
- Allergy to sirolimus or other rapamycin analogues.
- Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization.
- Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected.
- Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration).
- Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus.
- Patients who have a history of malignancy.
- Patients with an inability to participate or to follow the study treatment and assessment plan.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Low-Dose Sirolimus Plus Prednisolone
Participants receive oral sirolimus with dose adjustments to maintain a target plasma trough concentration of 4-8 ng/mL, in combination with prednisolone, for a treatment duration of 12 months.
|
Participants will receive oral sirolimus in combination with prednisolone.
Patients will be randomized in a 1:1 ratio to either a low-dose sirolimus group, with dose adjustments to maintain a target plasma trough concentration of 4-8 ng/mL, or a high-dose sirolimus group, with dose adjustments to maintain a target plasma trough concentration of 10-15 ng/mL.
Prednisolone will be administered according to the study protocol and tapered based on clinical response.
The total treatment duration will be 12 months.
|
|
Comparateur actif: High-Dose Sirolimus Plus Prednisolone
Participants receive oral sirolimus with dose adjustments to maintain a target plasma trough concentration of 10-15 ng/mL, in combination with prednisolone, for a treatment duration of 12 months.
|
Participants will receive oral sirolimus in combination with prednisolone.
Patients will be randomized in a 1:1 ratio to either a low-dose sirolimus group, with dose adjustments to maintain a target plasma trough concentration of 4-8 ng/mL, or a high-dose sirolimus group, with dose adjustments to maintain a target plasma trough concentration of 10-15 ng/mL.
Prednisolone will be administered according to the study protocol and tapered based on clinical response.
The total treatment duration will be 12 months.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Participants Achieving Platelet Count Recovery
Délai: 2 months
|
The proportion of participants who achieve platelet count recovery, defined as a platelet count ≥100 × 10⁹/L without platelet transfusion support, during the study period.
|
2 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Les changements dans les symptômes et/ou les complications du patient.
Délai: 6 et 12 mois
|
Amélioration de l'amplitude des mouvements.
|
6 et 12 mois
|
|
Fréquence des événements indésirables
Délai: 12 mois
|
Fréquence des événements indésirables (par ex.
troubles gastro-intestinaux, troubles du système sanguin et lymphatique, troubles métaboliques ou autres résultats de laboratoire anormaux, troubles cutanés et troubles généraux, etc.) recueillies par l'investigateur et rapportées par les parents.
Tous les événements indésirables ont été recueillis et classés selon les Critères communs de terminologie pour les événements indésirables, version 4.0 (CTCAE v4.0).
La causalité de l'événement indésirable a été déterminée par le personnel multidisciplinaire et a été classée comme définitivement non liée, probablement non liée, possiblement liée, probablement liée ou définitivement liée.
Toutes les réductions de dose, les interruptions ou les arrêts décidés à la discrétion des investigateurs ont été enregistrés.
|
12 mois
|
|
Qualité de vie (QOL) chez les patients.
Délai: 12 mois
|
Inventaire de la qualité de vie pédiatrique (PedsQLTM) 4.0 Échelles génétiques fondamentales pour nourrissons (
|
12 mois
|
|
Proportion of Participants Achieving Fibrinogen Recovery
Délai: 2 months
|
The proportion of participants who achieve fibrinogen recovery, defined as a plasma fibrinogen level ≥1.6 g/L without replacement therapy, during the study period.
|
2 months
|
|
Change in D-Dimer Level From Baseline
Délai: 2 months
|
Change in plasma D-dimer level from baseline to the specified study assessment time point.
|
2 months
|
|
Change in KHE Tumor Volume From Baseline
Délai: 6 and 12 months
|
Response to therapy was measured by volumetric magnetic resonance imaging (MRI) analyses were performed at baseline and 6 and 12 months after treatment and were independently assessed by 2 radiologists.
Changes in KHE size were classified as further growth (increase of ≥10%), no change (<10% increase and <10% decrease), partial involution (decrease of ≥10% and <75%), nearly complete involution (decrease of ≥75% and <100%), or complete involution (100%).
Photographs of the mixed KHE were taken at months 0, 6 and 12 by a medical photographer.
|
6 and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chaise d'étude: Yi Ji, West China Hospital
- Chercheur principal: Jiangyuan Zhou, MD, West China Hospital
Publications et liens utiles
Publications générales
- Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. 2020 Feb 3;15(1):39. doi: 10.1186/s13023-020-1320-1.
- Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer. 2017 Aug 15;141(4):848-855. doi: 10.1002/ijc.30775. Epub 2017 May 26.
- Wang Z, Yao W, Sun H, Dong K, Ma Y, Chen L, Zheng S, Li K. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019 Nov;46(11):956-961. doi: 10.1111/1346-8138.15076. Epub 2019 Sep 5.
- Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC 3rd. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013 Jan;162(1):142-7. doi: 10.1016/j.jpeds.2012.06.044. Epub 2012 Aug 4.
- Rossler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quere I, Baumgartner I, Niemeyer CM, Kapp FG. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. Pediatr Blood Cancer. 2021 Aug;68(8):e28936. doi: 10.1002/pbc.28936. Epub 2021 Feb 13.
- Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B, Qiu T, Gong X, Zhang Z, Lan Y, Hu F, Kong F, Qiu Q, Zhang Y. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022 Mar 17;139(11):1619-1630. doi: 10.1182/blood.2021014027.
- Lauven PM, Schwilden H, Stoeckel H. Threshold hypnotic concentration of methohexitone. Eur J Clin Pharmacol. 1987;33(3):261-5. doi: 10.1007/BF00637559.
- Ji Y, Chen S, Yang K, Zhou J, Zhang X, Jiang X, Xu X, Lu G, Qiu L, Kong F, Zhang Y. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021 Nov;74(5):1673-1681.e3. doi: 10.1016/j.jvs.2021.04.071. Epub 2021 May 31.
- Wada Y, Iijima K, Yonezawa T. [The effects of nitroglycerin induced hypotension on the tissue blood flow in dogs under halothane anesthesia]. Masui. 1985 Sep;34(9):1208-15. No abstract available. Japanese.
- Zhou J, Yang K, Dai S, Qiu T, Zhang X, Gong X, Chen S, Ji Y. Clinical features and management of kaposiform hemangioendothelioma and tufted angioma: Similarities and differences. J Am Acad Dermatol. 2022 Jul;87(1):172-174. doi: 10.1016/j.jaad.2021.07.012. Epub 2021 Jul 14. No abstract available.
- Zhou J, Qiu T, Zhang Z, Lan Y, Huo R, Xiang B, Chen S, Qiu L, Xia C, Xu X, Li J, Ma Y, Yao W, Wang Z, Dong C, Qin Z, Tai M, Guo L, He X, Gu S, Li L, Hou F, Cai Y, Wang H, Wang J, Jiang X, Zheng J, Li K, Ji Y. Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma. Int J Cancer. 2025 May 15;156(10):1986-1994. doi: 10.1002/ijc.35344. Epub 2025 Jan 20.
- Zhou J, Lan Y, Qiu T, Zhang Z, Gong X, Zhang X, Yang C, Zhou Z, Zhang Y, Yang M, Fu J, He C, Peng Q, Hu F, Xia C, Kong F, Chen S, Ji Y. Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: A randomized clinical trial. J Am Acad Dermatol. 2025 Jul;93(1):124-131. doi: 10.1016/j.jaad.2025.03.023. Epub 2025 Mar 17.
- Zhou J, Ji Y. Kaposiform hemangioendothelioma. J Am Acad Dermatol. 2026 Mar 12:S0190-9622(26)00396-8. doi: 10.1016/j.jaad.2026.03.020. Online ahead of print. No abstract available.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Cytopénie
- Tumeurs
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles des plaquettes sanguines
- Tumeurs, tissu vasculaire
- Thrombocytopénie
- Hémangiome
- Maladies hémiques et lymphatiques
- Syndrome de Kasabach Merritt
- Hémangioendothéliome kaposiforme
- Produits chimiques organiques
- Macrolides
- Lactones
- Sirolimus
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- RCT20260615
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .